Clinical trial
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
NCT02309580 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- May 8, 2023
- Enrollment
- 14 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed and refractory t-cell lymphoma, t-cell lymphoma